logo

IRON

Disc Medicine·NASDAQ
--
--(--)
--
--(--)
3.33 / 10
Netural

Disc Medicine's fundamentals score 3.3 out of 10, indicating significant room for improvement. Key weaknesses include a low Revenue-MV (-0.2574) and a sub-optimal Gross Profit Margin (36.70%), while Cash-MV (-0.0673) and Asset-MV (-0.5007) also lag. However, strengths in Profit-MV (0.4634) and high Fixed Assets Turnover (7979.42) provide some balance. Overall, the company's financial health is fragile, and any investment thesis must account for these fundamental challenges.

Fundamental(3.33)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score1/3
Weight9.23%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.11%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.71%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight13.82%
1M Return7.79%
PB-ROE
Value2.57
Score2/3
Weight19.41%
1M Return10.68%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.62%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.18%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight31.54%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight13.84%
1M Return7.73%
Net profit / Total profit (%)
Value100.18
Score2/3
Weight1.95%
1M Return1.28%
Is IRON undervalued or overvalued?
  • IRON scores 3.33/10 on fundamentals and holds a Fair valuation at present. Backed by its -29.82% ROE, 0.00% net margin, -16.62 P/E ratio, 5.25 P/B ratio, and -35.95% earnings growth, these metrics solidify its Netural investment rating.